Aclaris Therapeutics (ACRS) Cash from Financing Activities (2014 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly Cash from Financing Activities of $57.8 million in Q1 2026, up 2380.23% quarter-over-quarter from -$2.5 million in Q4 2025, and up 21111.27% on a YoY basis from N/an in Q1 2025.
Aclaris Therapeutics (ACRS) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $57.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 21111.27% year-over-year to $57.8 million; the TTM figure through Mar 2026 stood at $52.2 million (down 29.77% YoY), while the FY2025 annual figure was -$5.9 million, down 107.86% from the prior year.
- Cash from Financing Activities was $57.8 million for Q1 2026 at Aclaris Therapeutics, up from -$2.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $74.6 million in Q4 2024 to a low of -$3.0 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $13.3 million across 5 years, with a median of -$9000.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 152104.08% in 2024, then tumbled 13936.36% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $37000.0 in 2022, then soared by 32.43% to $49000.0 in 2023, then surged by 152104.08% to $74.6 million in 2024, then sank by 103.4% to -$2.5 million in 2025, then soared by 2380.23% to $57.8 million in 2026.
- The last three Cash from Financing Activities figures came in at $57.8 million (Q1 2026), -$2.5 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | 57.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.78 Mn |
| Mar 31, 2026 | 57.78 Mn |
| Dec 31, 2025 | -2.53 Mn |
| Dec 31, 2025 | -2.53 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | -275,000.00 |
| Mar 31, 2025 | -275,000.00 |
| Dec 31, 2024 | 74.58 Mn |
| Dec 31, 2024 | 74.58 Mn |
| Sep 30, 2024 | 22,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | -55,000.00 |
| Mar 31, 2024 | -55,000.00 |
| Dec 31, 2023 | 49,000.00 |
| Dec 31, 2023 | 49,000.00 |